Video

Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Related Videos
Brian I. Rini, MD, FASCO
Marc Machaalani, MD
Razane El Hajj Chehade, MD
Antonio Cigliola, MD
Brian I. Rini, MD, FASCO
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Toni K. Choueiri, MD
Neil J. Shah, MBBS
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope